
Keywords: استاتین; Atherogenic dyslipidaemia; Cardiovascular risk; Residual cardiovascular risk; Statin; Fenofibrate; Fenofibrate-statin combination therapy; Dislipemia aterogénica; Riesgo cardiovascular; Riesgo cardiovascular residual; Estatina; Fenofibrato; Terapia combi